# CCR 2025 mechanistic and methodological reading — 2026-09-23

These are source-grounded, newly written language frames, not verbatim quotations. Main-text reading is distinct from independent acceptance. Supplements were not provided/read. Bracketed values are placeholders, not transferable source results. Cross-tumor findings cannot become STK11/NSCLC evidence by analogy.

## PMID 39540841

Title: Aberrant Activation of Wound-Healing Programs within the Metastatic Niche Facilitates Lung Colonization by Osteosarcoma Cells. CCR 2025;31:414–429. DOI: 10.1158/1078-0432.CCR-24-0049. Source: 16-page typeset PDF; scientific text pp1–14; main Figures 1–6 visually inspected on pp5,7,9–11,13–14. No main tables. Supplementary Figures S1–S8 not read. Official category: Translational Cancer Mechanisms and Therapy. Disease: osteosarcoma lung metastasis, NOT primary lung cancer. Domains: single-cell/single-nucleus RNA sequencing; spatial transcriptomics; cell–cell communication inference; fibrosis; pharmacodynamic profiling; preclinical targeted therapy.

### Evidence and limits

- Tail-vein F420/K7M2/OS-17 models assess metastatic colonization, not the full spontaneous metastatic cascade. Matched primary tibial tumors provide a site-context comparison. Human metastatic specimens support cross-species concordance, not a lung-cancer cohort.
- Cell Ranger, Seurat/SCTransform, SingleR plus marker-based annotation, fgsea, NicheNet, AUCell and Visium/spacexr provide distinct analysis layers. Visium spots are multicellular; UMAP proximity does not prove lineage transition; predicted ligand–target activity does not establish direct receptor binding.
- Main Fig1 maps epithelial injury/cellular composition; Fig2 identifies DATP/basaloid states and spatial epithelial remodeling; Fig3 localizes scar-associated macrophages; Fig4 compares fibronectin with coculture/conditioned-medium validation; Fig5 tests lung tumor burden; Fig6 integrates spatial target activity and early/late nintedanib effects.
- Fig5: F420/K7M2 n=20 per treatment group; OS-17 n=5. Welch tests P=.0030/.0068/.0199. Tumor area, not overall survival, is the measured endpoint. Early preventive treatment cannot be described as regression of established metastases.
- Fig2G counts ~100 cells per animal with n=4 animals; Fig2I samples ≥10 regions per animal. Cells/regions are nested observations, not additional independent animals. Differential pathway scores likewise require animal-level replication before population-level inference.
- Nintedanib changes both tumor and niche compartments; target promiscuity limits attribution to a single kinase. Similar activity in immunocompetent/immunodeficient settings does not exclude immune contributions.
- Source discrepancy: Fig6C shows immediate treatment beginning day1, whereas Results p12 says day3. Do not reuse an exact immediate-treatment day without checking the experimental record. The RNA-QC wording refers to “mitochondrial DNA”; do not copy this into an RNA-seq protocol as a verified measurement.

### Abstract background

- `The host programs supporting metastatic colonization remain incompletely characterized.`

### Abstract methods

- `We integrated single-cell and spatial profiling with cross-model perturbation experiments.`

### Abstract results

- `Treatment reduced experimental metastatic burden and altered fibrogenic niche states.`

### Abstract conclusion

- `The findings nominate a microenvironmental vulnerability requiring clinical validation.`

### Introduction vocabulary

- `organ-specific permissiveness`
- `facultative repair`
- `maladaptive wound response`
- `epithelial–mesenchymal crosstalk`

### Introduction frames

- `Although [cell-intrinsic feature] is well characterized, how disseminated cells remodel [host compartment] remains unresolved.`
- `We asked whether a normally reparative program is persistently engaged during [disease process].`

### Methods vocabulary

- `reference-assisted annotation`
- `proportion-matched downsampling`
- `spatial deconvolution`
- `inferred ligand–target links`
- `blinded morphometry`
- `biological versus technical replication`

### Methods frames

- `Cell identities were assigned using [reference] and refined by canonical marker expression; spatial spots were deconvolved against [reference dataset].`
- `Candidate communication pathways were inferred computationally and evaluated using independent protein-level and perturbation assays.`
- `Analyses retained animal identity to distinguish within-animal sampling from independent replication.`

### Results vocabulary

- `border-restricted enrichment`
- `persistent transitional state`
- `tumor-derived matrix deposition`
- `cell-type-specific pathway attenuation`

### Results frames

- `[State] was enriched at the tumor–host interface, whereas [second program] was concentrated within the lesion core.`
- `Conditioned medium reproduced [phenotype], consistent with soluble-factor-mediated signaling without identifying its causal mediator.`
- `Reduced pathway activity coincided with changes in [cell population]; computational scores alone did not establish target engagement.`

### Discussion frames

- `These data support a model of reciprocal host–tumor signaling, while the mediators and directionality of individual interactions remain to be established.`
- `Because [drug] inhibits multiple kinases, the observed effect cannot be assigned uniquely to [one pathway].`
- `Concordance across models strengthens the mechanistic rationale, but generalization to other histologies requires direct testing.`

### Conclusion frames

- `Integrating spatial context with perturbation experiments identifies a candidate microenvironmental vulnerability in [model-defined disease].`

### Translational relevance frames

- `The findings motivate evaluation of niche-directed therapy, without establishing clinical efficacy or a validated predictive biomarker.`

### Results paragraph

- `Single-cell profiling identified [transitional epithelial state] and [macrophage state] in metastatic lesions. Spatial analysis localized these populations to [anatomic compartment], and orthogonal staining confirmed [protein-level feature]. Treatment reduced [burden metric] while attenuating [inferred pathway program]. These observations link niche remodeling to experimental progression, but do not resolve the contribution of each inhibited target.`

### Discussion paragraph

- `The integration of cell-state, spatial, and perturbation data supports a role for maladaptive tissue repair in metastatic colonization. Nevertheless, intravenous implantation bypasses early dissemination, and spatial co-localization does not itself establish signaling direction. Extension to primary NSCLC or STK11-associated disease therefore requires separate evidence rather than a change of disease labels.`

## PMID 39841860

Title: Pretargeted Trop-2 immunoPET for rapid, selective detection of pancreatic tumors. CCR 2025;31:2719–2726. DOI: 10.1158/1078-0432.CCR-24-3098. Source: 17-page author manuscript, NOT version of record; scientific text pp1–10, Translational Relevance p13; Figures 1–3 and legends pp14–17 visually inspected. No main tables. Supplementary Figures 1–4/Tables 1–2 referenced but not read. Main disease: pancreatic xenografts; PC3/OVCAR3 comparators and Calu6 lung-cancer negative-control model. This is cross-tumor imaging-method evidence with an actual lung-model comparator, not a lung therapeutic-efficacy study. Existing official category retained only with its existing verified provenance.

### Evidence and limits

- Trop-2.2 binding assessed by recombinant-protein/bead and cellular assays, western blot, imaging and terminal biodistribution. Calu6 is Trop-2-negative; do not infer that NSCLC in general lacks Trop-2. The Fig1A legend calls its OD405/concentration assay surface plasmon resonance; do not treat a binding curve as a reported kinetic KD without further source clarification.
- Random lysine and engineered-cysteine conjugation were compared, alongside 89Zr/64Cu/18F configurations. The site-selective conjugates did not improve tumor targeting; chemical uniformity is not equivalent to superior in-vivo performance.
- Direct 89Zr conjugates accumulated from ~3h; BxPC-3 tumor uptake reached 75–100% injected dose per gram at later points. %ID/g is concentration normalized to tissue mass, not the fraction of all injected activity; values near/above100 do not imply >100% whole-dose recovery.
- 64Cu-Sar-Tz performed best among tested pretargeting constructs, but direct 89Zr labeling had superior tumor-to-organ ratios in this particular model. “Best pretargeting construct” does not mean globally best imaging method.
- Fig1 assays use n=3 technical replicates, Fig2 n=5 mice per timepoint/group, Fig3 n=4 per imaging group. Different color-scale maxima preclude comparing apparent brightness as quantitative uptake. No diagnostic sensitivity/specificity, clinical response prediction or therapeutic efficacy was established.
- Uptake assays did not cleanly distinguish surface-bound from internalized activity; higher binding at4°C cannot simply prove faster internalization. No in-vivo blocking/IgG control; alternative negative-target models partly address specificity. Potential lower radiation burden is a rationale, not established patient dosimetry.

### Abstract background

- `Antibody residence time can constrain the timing of target-directed imaging.`

### Abstract methods

- `We compared direct labeling and pretargeting using binding assays, imaging, and biodistribution.`

### Abstract results

- `Performance varied by construct and model, with no universal superiority across tissue ratios.`

### Abstract conclusion

- `The results establish preclinical imaging feasibility rather than clinical predictive utility.`

### Introduction vocabulary

- `target heterogeneity`
- `prolonged blood-pool residence`
- `biological versus physical half-life`
- `companion-imaging rationale`

### Introduction frames

- `A target-directed imaging strategy may complement tissue assays, but its ability to predict therapeutic response requires prospective validation.`

### Methods vocabulary

- `site-selective bioconjugation`
- `degree of labeling`
- `radiochemical purity`
- `antigen-blocking control`
- `terminal biodistribution`
- `injected dose per gram`

### Methods frames

- `Uptake was normalized to injected activity and tissue mass, with biological and technical replicate counts reported separately.`
- `The interval from antibody administration was distinguished from the interval after radioligand injection.`

### Results vocabulary

- `target-dependent accumulation`
- `off-tumor distribution`
- `renal/hepatobiliary clearance`
- `retained binding after conjugation`
- `model-dependent uptake kinetics`

### Results frames

- `[Modification] preserved binding in vitro but did not improve tumor delivery in vivo.`
- `Among pretargeted constructs, [agent] produced higher contrast; however, direct labeling retained an advantage in [specific ratio].`
- `Low signal in the antigen-negative comparator supported specificity, without excluding all nonspecific retention mechanisms.`

### Discussion frames

- `The unusually rapid uptake may reflect target abundance, internalization, or model-specific vascular features; these explanations were not individually resolved.`
- `Improved chemical homogeneity did not translate into improved biological performance in the tested setting.`
- `A potential companion diagnostic must be evaluated against clinical response rather than target visualization alone.`

### Conclusion frames

- `These preclinical findings establish imaging feasibility while leaving diagnostic accuracy and patient-selection utility unresolved.`

### Translational relevance frames

- `Target-directed imaging could support prospective assessment of antigen distribution, provided its predictive utility is independently validated.`

### Results paragraph

- `Radiolabeling preserved [binding measure], and uptake tracked target expression across positive and negative models. Serial imaging revealed [time-dependent pattern], corroborated by ex-vivo biodistribution. The preferred pretargeting construct was not superior to direct labeling for every tissue ratio, indicating that tracer selection depends on the intended imaging interval and endpoint.`

### Discussion paragraph

- `The imaging strategy separates antibody localization from radionuclide delivery, offering flexibility in tracer selection. However, the high-uptake pancreatic model may not represent lower-expressing tumors, and technical replicates do not substitute for independent animal validation. Application to STK11-associated NSCLC should therefore be restricted to methodological language unless target and outcome data are available in that population.`

## PMID 39704655

Title: Smoking carcinogen induced inflammation promotes lung carcinogenesis via IRAK4 activation. CCR 2025;31:746–755. DOI: 10.1158/1078-0432.CCR-24-2182. Source: 18-page author manuscript; scientific text pp1–9, Translational Relevance p11; Figures 1–6 pp12–17 and Table1 p18 visually inspected. Supplementary figures/data files not provided/read. Domains: lung carcinogenesis; inflammatory signaling; microtubule-enriched phosphoproteomics; genetic/pharmacologic perturbation; preclinical targeted therapy. Human IHC cohort is SCLC, whereas H23/H358 are NSCLC models; do not collapse their histologies.

### Evidence and limits

- Chronic intratracheal NNK/BaP exposure: 50 treated versus25 vehicle mice, with small serial-sacrifice subsets. Fig1 reduced survival and evolving histology, Fig2 myeloid infiltration/IL-1β, Fig3 IRAK4 IHC in43 human tumors, Fig4 fractionation/localization, Fig5 phosphopeptides, Fig6 genetic invasion assays and H23 xenografts (n=5/arm).
- Microtubules isolated using taxol/GTP and ultracentrifugation; S-trap digestion/TiO2 enrichment; Orbitrap DDA; SEQUEST/SwissProt; 1% peptide/protein identification FDR. This FDR does NOT mean all differential-phosphorylation tests were multiplicity-corrected: abundance testing used heteroscedastic t-tests at P<.05. Mean-centering and low-intensity imputation influence fold changes; normality was assumed, not tested. PRIDE PXD053181 is a data-access pointer, not a dataset reanalysis performed here.
- MYH9-S1943 phosphopeptide abundance declined in both H23/H358 after emavusertib. Association with inhibition does not establish direct kinase–substrate phosphorylation; purified-enzyme/rescue tests would be required. Decreased phosphopeptide abundance can also reflect protein abundance, fraction recovery or indirect signaling.
- Genetic depletion reduced Matrigel invasion and drug treatment reduced xenograft growth. The experiments do not directly demonstrate prevention of carcinogen-induced tumors by IRAK4 inhibition in the chronic-exposure model, and do not establish patient benefit.
- Source flags: abstract18months versus Methods110weeks (follow-up/sampling context must be specified); prose says8-month dysplasia but Table1 has vascular congestion/no abnormality at8months, with dysplasia at12months. Discussion calls IL-1β-producing cells epithelial while Methods/Results/Fig2 describe macrophages. Human IHC total IRAK4 expression is not equivalent to a validated phospho-activation assay. KO/knockdown and vector descriptions are inconsistent; preserve “genetic depletion” rather than reproduce an unverified editing protocol. Precursor tolerance printed “10 pm” is not a verified instrument unit.

### Abstract background

- `The signaling events connecting carcinogen exposure with tumor-cell behavior remain incompletely defined.`

### Abstract methods

- `A chronic exposure model was combined with tissue profiling, phosphoproteomics, and functional perturbation.`

### Abstract results

- `Target inhibition was accompanied by phosphosite changes and reduced experimental growth or invasion.`

### Abstract conclusion

- `The data support preclinical target nomination without proving clinical benefit or direct substrate specificity.`

### Introduction vocabulary

- `inflammation-linked transformation`
- `exposure-to-phenotype connection`
- `early neoplastic remodeling`

### Introduction frames

- `The epidemiologic association between [exposure] and [disease] is established, but the intervening signaling events remain incompletely defined.`

### Methods vocabulary

- `subcellular fraction enrichment`
- `phosphopeptide capture`
- `target–decoy identification control`
- `intensity normalization`
- `low-abundance imputation`

### Methods frames

- `Identification-level FDR was controlled separately from differential-abundance testing; the latter used [test and multiplicity procedure actually performed].`
- `Phosphopeptide abundance was interpreted alongside total protein abundance and fractionation controls where available.`

### Results vocabulary

- `concordant phosphosite changes`
- `attenuated invasive capacity`
- `compartment-associated localization`
- `reduced xenograft expansion`

### Results frames

- `[Phosphosite] decreased after treatment in both models, nominating a downstream response rather than proving a direct substrate relationship.`
- `Genetic depletion reduced invasion, and pharmacologic inhibition independently limited tumor growth in [model].`

### Discussion frames

- `Convergent perturbation data strengthen target nomination, although direct substrate specificity and the full exposure-to-tumor causal chain remain unresolved.`
- `The human expression cohort and experimental models represent different histologies, which limits direct cross-system extrapolation.`

### Conclusion frames

- `These observations provide a preclinical rationale for further testing of [axis] in explicitly defined lung-cancer settings.`

### Translational relevance frames

- `Tissue expression and model sensitivity justify prospective investigation, not treatment selection based on expression alone.`

### Results paragraph

- `Exposure was accompanied by [inflammatory phenotype] and increased [tissue marker]. Subcellular enrichment localized [candidate] to [fraction], and phosphoproteomic profiling identified concordant treatment-associated changes at [site]. Genetic depletion and drug treatment reduced distinct functional endpoints, providing complementary evidence without resolving direct kinase–substrate relationships.`

### Discussion paragraph

- `The experimental sequence connects chronic exposure, inflammatory signaling, and tumor-cell behavior, but each link has a different evidentiary basis. Differential phosphopeptide abundance is not synonymous with altered site occupancy, and identification FDR does not correct the subsequent hypothesis tests. These distinctions should remain explicit when adapting the language to STK11-associated proteomic findings.`

## PMID 40465424

Title: STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20–Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models. CCR2025;31:3002–3018. DOI:10.1158/1078-0432.CCR-24-3833. Source:17-page typeset PDF, scientific text pp1–15; Figures1–6 visually inspected pp7–11,14; no main tables. Supplementary methods/Figures/Tables not supplied/read. Official category: Translational Cancer Mechanisms and Therapy. Domains: structural biology; molecular dynamics; chemoproteomics; mutant-selective targeted therapy; isogenic controls; pharmacodynamics.

### Evidence and limits

- Crystal structures plus five1.5-μs metadynamics replicates/system suggest near-loop exon20 insertion variants favor active/intermediate αC-helix states. These are simulation-derived state probabilities, not patient variant frequencies. Far-loop structures were not obtained, so their dynamic mechanism remains a hypothesis.
- Fig2: biochemical kinact/KI selectivity for NPG versusWT at1mM ATP is19-fold for STX-721; kinome binding panel468kinases at3μM; live-cell competitive chemoproteomics profiles16,859 cysteines (n≥4), with EGFR-C797 a prominent hit. Quantified cysteines do not exhaust the proteome. DUSP4 peptide changes can reflect abundance changes rather than direct covalent binding.
- TMT activity-based profiling, MSFragger/X!Tandem/Comet/MS-GF+, cell-line-specific FASTA including mutant sequences, PeptideProphet/iProphet target–decoy1% peptide-ion FDR, isotopic-impurity correction. Do not describe a single-gene qPCR assay as transcriptomics or the entire experiment as clinical multiomics.
- Cell selectivity is geometric mean IC50(WT)/IC50(mutant) with log-scale CIs, not absolute potency. Osimertinib L858R/T790M benchmark29-fold inBa/F3 but6-fold inhuman cells illustrates model dependence. Near-/far-loop response varies; C797S removes covalent mechanism selectivity. NCI-H2073 isogenic knock-in controls are stronger than unrelated WT lines.
- Fig5 LU0387 n10/group; CTG2842 andMGH10080 n8;GFmodel10(9vehicle);HER2model9; PDn3. Fig6 isogenicCDX n6/arm. Tumor regression and reduced WT-dependent growth effects in mice do not prove fewer patient adverse events. No CNS penetrance data or clinical response data in this paper. Cell-autonomous proliferation assays cannot fairly rank amivantamab's immune-mediated efficacy.
- Source flags: Fig6C prints percent change using final volume as denominator, inconsistent with a baseline-relative label and changes>100%; do not copy the formula. Methods qPCR prints2^ΔCt despite definingΔCt=target–reference; verify sign before method reuse. AlphaLISA reports1μg/mL ×10μL as10μg, an inconsistent amount. Body-weight “change” formula omits baseline subtraction. Keep all these formulas out of reusable templates pending resolution.

### Abstract background

- `Wild-type inhibition can constrain the therapeutic window of mutation-directed agents.`

### Abstract methods

- `Structural, chemoproteomic, and matched-cell assays were used to evaluate mutant selectivity.`

### Abstract results

- `Selectivity was retained in several human models but varied across variant subclasses.`

### Abstract conclusion

- `These preclinical findings support genotype-defined evaluation while clinical tolerability remains unresolved.`

### Introduction vocabulary

- `therapeutic-window constraint`
- `ATP-competitive binding`
- `genotype-specific vulnerability`
- `conformational-state occupancy`

### Introduction frames

- `Potency against [mutant] alone may be insufficient when effective exposures also inhibit the wild-type protein required for normal tissue function.`

### Methods vocabulary

- `enhanced-sampling simulation`
- `collective variable`
- `geometric-mean selectivity ratio`
- `competitive cysteine engagement`
- `variant-aware sequence database`
- `isotopic impurity correction`

### Methods frames

- `Mutant selectivity was calculated within matched assay conditions as the ratio of wild-type to mutant IC50 values, with uncertainty estimated on the logarithmic scale.`
- `Probe competition was evaluated alongside changes in total protein abundance to distinguish target engagement from altered expression.`
- `Biological replicates, technical replicates, simulation trajectories and independent disease models were enumerated separately.`

### Results vocabulary

- `preferential state sampling`
- `covalent-site dependence`
- `sustained pathway suppression`
- `assay-context-dependent selectivity`
- `near-loop/far-loop heterogeneity`

### Results frames

- `Selectivity decreased in [variant subgroup], indicating that activity was not uniform across the mutation class.`
- `Target-pathway suppression persisted beyond [exposure interval], consistent with—but not uniquely proving—the proposed irreversible mechanism.`
- `Matched isogenic models retained a differential response, reducing confounding by unrelated genetic backgrounds.`

### Discussion frames

- `Structural observations offer a mechanistic model for selectivity, but uncharacterized variants may occupy different conformational states.`
- `Improved preclinical wild-type sparing may widen the therapeutic window; its clinical magnitude remains to be established.`
- `Comparators with immune-dependent mechanisms cannot be ranked solely using cell-autonomous viability assays.`

### Conclusion frames

- `The concordance of structural, engagement, and functional readouts supports further evaluation in the specified molecular subgroup.`

### Translational relevance frames

- `Mutation-selective activity motivates genotype-defined development, while safety, CNS activity, and clinical benefit require direct assessment.`

### Results paragraph

- `Enhanced-sampling simulations suggested that [variants] preferentially occupied [conformation]. Competitive profiling identified [site] engagement, while matched-cell assays demonstrated [selectivity ratio]. The effect varied across variant subclasses and remained evident in isogenic xenografts. These results support a mutation-selective mechanism without establishing clinical superiority.`

### Discussion paragraph

- `The use of structural models, variant-aware chemoproteomics, and matched functional controls strengthens the mechanistic argument. Nonetheless, state probabilities depend on the simulation framework, probe competition can be confounded by abundance, and mouse tolerability is an imperfect proxy for human safety. For STK11 work, this paper is most useful for the logic of matched comparisons and orthogonal validation, not for borrowing EGFR-specific efficacy claims.`

## PMID 39879384

Title: Targeting AXL inhibits the growth and metastasis of prostate cancer in bone. CCR2025;31:1346–1358. DOI:10.1158/1078-0432.CCR-24-3028. Source:26-page author manuscript, scientific text pp1–13, Translational Relevance p17, Figures1–6 including embedded clinical/model tables visually inspected pp18–26. Supplements not supplied/read. Disease: prostate cancer, CRPC/NEPC, bone tumors with secondary lung metastases; NOT primary NSCLC. Domains: bulk RNA-seq; xenograft species deconvolution; IHC/phosphoprotein validation; prognostic modeling; preclinical combinations. Targeted immunoblots are not untargeted proteomics despite broad wording in Discussion.

### Evidence and limits

- Human bone-biopsy cohort31: pAXLhigh19/low12. Fig1F adjusted Cox HR26.9(95%CI3.03–238.4), P=.003; unadjusted29.3(3.61–237.7), P=.002. Very wide intervals and small sample with multiple covariates imply imprecision/overfitting risk. A prognostic association is not a predictive biomarker of batiraxcept benefit. Results incorrectly calls the models logistic; Methods and HR output indicate Cox regression.
- Five LuCaP PDX models, fouradenocarcinoma andoneNEPC; intratibial implantation bypasses initial bone homing. Soluble AXL decoy sequestersGAS6 rather than directly inhibiting the kinase. Combination effects vary by endpoint: NEPC bioluminescence combination versusbatiraxcept alone not significant, but Ku70 area differs. Do not equate stronger combination effects with formal pharmacologic synergy.
- Lung tumor burden measured by human/universalGAPDH and species-specificKu70/lineage markers. Fig3C/D normalized to combination=1;Fig3F to docetaxel=1;Fig4F to carboplatin=1. These relative transcript ratios are not absolute tumor-cell percentages without calibration.
- RNA-seq: paired-end150bp, humanhg38/mousemm10alignment, XenofilteR, HISAT2/featureCounts, two biological replicates/condition, DESeq2 BH-adjustedP≤.05. FPKM is an expression summary, not specified as DESeq2's count input. GSEA uses separate thresholds (reported adjustedP<.05,FDR<.25). Pathway enrichment nominates necroptosis but does not prove execution of cell death without functional testing.
- Fig5 stemness-associated transcripts/proteins;Fig6 phosphoAXL/AKT/ERK andE2F1/NUSAP1. Marker reduction does not prove eradication of cancer stem cells or immune-cell reprogramming. Immunodeficient hosts limit immune inference. No observed weight change does not establish absence of toxicity.
- Source flags: Methods/experimental schematic2×10^5cells versusFig4legend1×10^5;Fig4 saysday30afterimplantation whereas timeline starts treatmentday31andendsday60. Do not reuse exact inoculum/timing without verification. Discussion references a negative ovarian phaseIII primary endpoint and favorable exploratory subgroup; the subgroup cannot overturn the primary result or validate treatment selection in prostate cancer.

### Abstract background

- `Niche-dependent signaling may contribute to treatment resistance in metastatic disease.`

### Abstract methods

- `Clinical associations were evaluated separately from treatment responses and transcriptomic changes in patient-derived models.`

### Abstract results

- `Treatment altered tumor burden and molecular programs, with endpoint-dependent combination effects.`

### Abstract conclusion

- `The findings motivate prospective testing but do not establish a predictive treatment-selection biomarker.`

### Introduction vocabulary

- `lineage plasticity`
- `castration-resistant progression`
- `niche-derived ligand availability`
- `treatment-associated stem-like programs`

### Introduction frames

- `Whether [pathway] contributes to treatment resistance in [anatomic niche] remains unresolved despite its association with aggressive disease.`

### Methods vocabulary

- `species-aware alignment`
- `host-read removal`
- `count-based differential expression`
- `reference-normalized transcript abundance`
- `covariate-adjusted hazard model`

### Methods frames

- `Reads were aligned to both host and human references, and host-derived reads were removed before tumor-focused expression analysis.`
- `Differential expression used raw gene counts with [multiplicity correction], whereas normalized expression values were used for visualization.`
- `Survival associations were estimated using Cox models with explicitly listed covariates and confidence intervals.`

### Results vocabulary

- `attenuated pathway phosphorylation`
- `endpoint-dependent combination effect`
- `imprecise adjusted estimate`
- `reduced stemness-associated expression`

### Results frames

- `The adjusted association remained detectable, although the wide confidence interval indicated substantial uncertainty.`
- `The combination reduced [histologic endpoint] beyond monotherapy, whereas the corresponding difference in [imaging endpoint] was not significant.`
- `Enrichment analysis implicated [program], and targeted protein assays provided complementary evidence of pathway modulation.`

### Discussion frames

- `A prognostic association and preclinical sensitivity do not establish that the marker predicts differential treatment benefit in patients.`
- `Enhanced combination activity should not be described as synergy without a prespecified interaction framework.`
- `The small discovery cohort and limited transcriptomic replication warrant independent validation.`

### Conclusion frames

- `These findings support further testing of [pathway-directed strategy] in the model-defined disease setting, without establishing clinical benefit.`

### Translational relevance frames

- `The integrated clinical and experimental evidence provides a rationale for prospective testing, with biomarker selection remaining investigational.`

### Results paragraph

- `[Marker] was associated with outcome in a small clinical cohort, with a wide adjusted confidence interval. In patient-derived models, treatment reduced [burden measure] and altered [transcript program]. Species-aware RNA analysis and protein-level assays supported pathway modulation, but effects differed between imaging and histologic endpoints.`

### Discussion paragraph

- `The findings connect niche signaling with treatment response, while leaving clinical predictive value unresolved. Intratibial implantation bypasses early dissemination, RNA-derived burden measures require calibration, and a two-replicate transcriptomic experiment provides limited precision. The article can inform STK11 manuscript organization and analytical wording, but prostate-specific findings must not be presented as NSCLC evidence.`

